Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Ann Intern Med. 2020 Nov 3;173(9):W147-W148. doi: 10.7326/L20-1177. Epub 2020 Sep 22.

Authors

Katherine Mackey¹, Devan Kansagara¹, Kathryn Vela¹

Affiliation

¹ VA Portland Health Care System, Portland, Oregon (K.M., D.K., K.V.).

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Angiotensin Receptor Antagonists / adverse effects
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensins
Betacoronavirus
COVID-19
Coronavirus Infections* / epidemiology
Humans
Pandemics*
Pneumonia, Viral* / epidemiology
Renin-Angiotensin System
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins